News

Novo Nordisk slashed its financial forecasts as it struggled to fight off competition in the United States. It also named a ...
The sell-off erased an estimated $70 billion in market value, slashing Novo Nordisk's valuation to around $287 billion, down ...
Novo Nordisk faces slowing demand, rising competition, and CEO transition. Learn about challenges impacting its growth and ...
Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...
Shares of Novo Nordisk are trading lower Wednesday morning. The stock is extending a dramatic sell-off from Tuesday's session ...
Novo Nordisk said it expects weaker sales growth of its popular weight-loss drug Wegovy due to competition from copycat drugs ...
Shares in Novo Nordisk fell as much as 30% after it slashed sales and profits forecasts for the second time this year amid ...
The pharmaceutical giant cut its guidance and said U.S. sales of Ozempic grew more slowly.
The drugmaker unexpectedly cuts its full-year guidance, citing lower sales expectations for its blockbuster drugs Wegovy and ...